Skip to contentSkip to Braille Studio

Library / Laws / 117th Congress / Senate Bills / S. 1428

S. 1428

To prohibit brand name drug companies from compensating generic drug companies to delay the entry of a generic drug into the market, and to prohibit biological product manufacturers from compensating biosimilar and interchangeable companies to delay the entry of biosimilar biological products and interchangeable biological products.

Print stageDateSize⠃
Introduced in Senate2021-04-2820.3K⠃⠗⠋
Reported in Senate2021-04-2843.5K⠃⠗⠋